随着BITE在儿童桌上,CAR在儿科B-ALL的位置是什么?
Amanda M Li1, Shannon L Maude2,3
1British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
Hematology. American Society of Hematology. Education Program
|December 5, 2025
概括
像blinatumomab和CAR T细胞疗法这样的T细胞参与免疫疗法正在改变儿科B细胞急性淋巴细胞白血病 (B-ALL) 治疗. 它们在前线和复发环境中的最佳使用需要进一步调查.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 儿科血液学 儿科血液学
背景情况:
- 参与T细胞免疫疗法显著改善了儿科B细胞急性淋巴细胞白血病 (B-ALL) 的结果.
- 这些疗法,包括blinatumomab和仿真抗原受体 (CAR) T细胞疗法,越来越多地用于前线和复发/耐药的环境.
- 布利纳图莫马布 (双特异性T细胞参与者) 已获得FDA批准,用于B-ALL的缓解巩固,而CAR T细胞疗法已被批准用于耐药或复发的B-ALL.
研究的目的:
- 审查关于小儿B-ALL.Blinatumomab和CAR T细胞治疗的最新数据.
- 讨论CAR T细胞治疗在当前治疗环境中的不断变化的作用.
- 为了解决这些免疫疗法不清楚的最佳放置和序列.
主要方法:
- 最近临床数据的文献综述和布利纳图马布和CAR T细胞治疗的扩大使用.
- 对当前儿科B-ALL治疗指南和新兴研究的分析.
- 对复发性/耐药性疾病和高风险人群的治疗策略的讨论.
主要成果:
- 布利纳莫马布广泛用于B-ALL.前线治疗.
- 卡尔T细胞疗法是治疗耐药/复发的儿科B-ALL的已知选择.
- 这些疗法的最佳测序和整合仍然是积极研究和临床考虑的领域.
结论:
- 布莱纳托马布和CAR T细胞疗法代表了儿科B-ALL治疗的重大进展.
- 需要进一步的研究来确定在不同疾病环境中利用这些免疫疗法的最佳策略.
- 卡尔T细胞疗法在治疗复发性/耐药性和高风险儿科B-ALL患者方面发挥着至关重要的作用.
相关概念视频
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
231
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
231
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
176
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
176
01:35Pedigree Analysis
88.7K
Overview
88.7K
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
244
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
244
01:29Drug Dosing: Infants and Children
234
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
234
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
195
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
195